Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation

Sia V. Lindskrog; Trine Strandgaard; Iver Nordentoft; Matthew D. Galsky; Thomas Powles; Mads Agerbæk; Jørgen Bjerggaard Jensen; Catherine Alix-Panabières; Lars Dyrskjøt

doi:10.1038/s41585-025-01023-9

Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation

Sia V. Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew D. Galsky, Thomas Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières, Lars Dyrskjøt^*

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

1 Citation (Scopus)

Abstract

Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.

Original language	English
Article number	5068
Journal	Nature Reviews Urology
ISSN	1759-4812
DOIs	https://doi.org/10.1038/s41585-025-01023-9
Publication status	E-pub / Early view - 2025

Access to Document

10.1038/s41585-025-01023-9

Cite this

Lindskrog, S. V., Strandgaard, T., Nordentoft, I., Galsky, M. D., Powles, T., Agerbæk, M., Jensen, J. B., Alix-Panabières, C., & Dyrskjøt, L. (2025). Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation. Nature Reviews Urology, Article 5068. Advance online publication. https://doi.org/10.1038/s41585-025-01023-9

@article{0aa98a32b2724331b6524b9852d2dc7d,

title = "Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation",

abstract = "Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.",

author = "Lindskrog, {Sia V.} and Trine Strandgaard and Iver Nordentoft and Galsky, {Matthew D.} and Thomas Powles and Mads Agerb{\ae}k and Jensen, {J{\o}rgen Bjerggaard} and Catherine Alix-Panabi{\`e}res and Lars Dyrskj{\o}t",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2025.",

year = "2025",

doi = "10.1038/s41585-025-01023-9",

language = "English",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Research",

}

TY - JOUR

T1 - Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation

AU - Lindskrog, Sia V.

AU - Strandgaard, Trine

AU - Nordentoft, Iver

AU - Galsky, Matthew D.

AU - Powles, Thomas

AU - Agerbæk, Mads

AU - Jensen, Jørgen Bjerggaard

AU - Alix-Panabières, Catherine

AU - Dyrskjøt, Lars

PY - 2025

Y1 - 2025

N2 - Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.

AB - Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.

UR - http://www.scopus.com/inward/record.url?scp=105002590192&partnerID=8YFLogxK

U2 - 10.1038/s41585-025-01023-9

DO - 10.1038/s41585-025-01023-9

M3 - Review

C2 - 40234713

AN - SCOPUS:105002590192

SN - 1759-4812

JO - Nature Reviews Urology

JF - Nature Reviews Urology

M1 - 5068

ER -

Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this